Parkman Healthcare Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Parkman Healthcare Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,955	Closed	-$2.07M	–	96
2025 Q1	$2.07M	Buy	100,955 +24,839	+33%	+$552K	0.25%	75
2024 Q4	$1.96M	Sell	76,116 -29,218	-28%	-$621K	0.26%	73
2024 Q3	$1.75M	Sell	105,334 -30,042	-22%	-$520K	0.22%	79
2024 Q2	$2.6M	Sell	135,376 -64,935	-32%	-$1.3M	0.35%	69
2024 Q1	$4.74M	Sell	200,311 -100,439	-33%	-$2.04M	0.58%	57
2023 Q4	$3.36M	Buy	300,750 +51,726	+21%	+$474K	0.47%	64
2023 Q3	$2.3M	Buy	249,024 +9,973	+4%	+$108K	0.42%	67
2023 Q2	$2.84M	Buy	239,051 +124,051	+108%	+$1.65M	0.49%	61
2023 Q1	$1.52M	Buy	+115,000	New	+$1.45M	0.33%	66

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Parkman Healthcare Partners's NAMS Position: Q2 2025 in Review

Parkman Healthcare Partners sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 100,955 shares — an estimated $2.07M sold.

Parkman Healthcare Partners first reported a position in NAMS in Q1 2023 and held it in 9 quarters. The position peaked at $4.74M in Q1 2024. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

Parkman Healthcare Partners reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 100,955 NewAmsterdam Pharma shares in Q2 2025, an estimated $2.07M.
Parkman Healthcare Partners first reported a position in NewAmsterdam Pharma in Q1 2023 and held it in 9 quarters.
Parkman Healthcare Partners's NewAmsterdam Pharma position peaked at $4.74M in Q1 2024.
131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.